Stealth liposomes for the delivery of zoledronic acid into tumors enhance the anticancer activity of the drug


https://doi.org/10.4081/tmr.6596
Vol. 4 No. 1 (2020)
Submitted: 24 January 2017
Accepted: 24 February 2017
Published: 19 July 2017
Breast cancer, Drug delivery, Lung cancer, Stealth liposomes, Zoledronic acid
Abstract Views: 924
PDF: 529
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • Silvia Zappavigna
    silvia.zappa@libero.it
    Department of Biochemistry, Biophysics and General Pathology, University of Campania L. Vanvitelli, Naples, Italy.
  • Amalia Luce Department of Biochemistry, Biophysics and General Pathology, University of Campania L. Vanvitelli, Naples, Italy.
  • Manuela Porru Experimental Chemotherapy Laboratory, Regina Elena Cancer Institute, Rome, Italy.
  • Alessia M. Cossu Department of Biochemistry, Biophysics and General Pathology, University of Campania L. Vanvitelli, Naples, Italy.
  • Carmela Ferri Department of Biochemistry, Biophysics and General Pathology, University of Campania L. Vanvitelli, Naples, Italy.
  • Sara Lusa Department of Pharmacy University of Naples "Federico II", Naples, Italy.
  • Marianna Abate Department of Biochemistry, Biophysics and General Pathology, University of Campania L. Vanvitelli, Naples, Italy.
  • Giuseppe De Rosa Department of Pharmacy, Federico II University of Naples, Naples, Italy.
  • Michele Caraglia Department of Biochemistry, Biophysics and General Pathology, University of Campania L. Vanvitelli, Naples, Italy.
  • Carlo Leonetti Experimental Chemotherapy Laboratory, Regina Elena Cancer Institute, Rome, Italy.
Zoledronic acid (ZOL) is a third generation aminobisphosphonate, commonly used for the treatment of bone metastases. Several studies have shown a direct in vitro antitumor activity of ZOL but a clear evidence of clinical activity is still lacking. Unfortunately, the use of ZOL as an anticancer agent in extraskeletal tissues is limited probably because it is rapidly removed from the blood and tends to accumulate in the bone. On these bases, we developed stealth liposomes encapsulating ZOL (Lipo- ZOL) to improve the pharmacokinetic profile of the drug. Compared to free ZOL, Lipo-ZOL induced a stronger inhibition of growth in two different cancer cell lines H460 and CG5. Moreover, Lipo-ZOL also significantly caused a larger inhibition of tumor growth and increased the overall survival in murine models of human lung and breast cancer, in comparison with free ZOL. These results suggest the use of Lipo-ZOL as a potential anticancer agent in patients with neoplastic disease.

Silvia Zappavigna, Department of Biochemistry, Biophysics and General Pathology, University of Campania L. Vanvitelli, Naples

Assistant Professor, Department of Biochemistry, Biophysics and General Pathology

Second University of Naples

Zappavigna, S., Luce, A., Porru, M., Cossu, A. M., Ferri, C., Lusa, S., Abate, M., De Rosa, G., Caraglia, M., & Leonetti, C. (2017). Stealth liposomes for the delivery of zoledronic acid into tumors enhance the anticancer activity of the drug. Translational Medicine Reports, 4(1). https://doi.org/10.4081/tmr.6596

Copyright (c) 2017 Silvia Zappavigna, Amalia Luce, Manuela Porru, Alessia Maria Cossu, Carmela Ferri, Sara Lusa, Marianna Abate, Giuseppe De Rosa, Michele Caraglia, Carlo Leonetti

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC